Clover Health Investments, Corp. (NASDAQ:CLOV) Director Carladenise Armbrister Edwards Sells 200,000 Shares

Clover Health Investments, Corp. (NASDAQ:CLOV) Director Carladenise Armbrister Edwards sold 200,000 shares of Clover Health Investments stock in a transaction on Friday, March 7th. The shares were sold at an average price of $3.61, for a total transaction of $722,000.00. Following the completion of the sale, the director now directly owns 273,227 shares of the company’s stock, valued at approximately $986,349.47. The trade was a 42.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Clover Health Investments Price Performance

Shares of NASDAQ CLOV traded down $0.03 during trading hours on Tuesday, hitting $3.36. 7,380,740 shares of the company’s stock were exchanged, compared to its average volume of 6,428,973. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -16.80 and a beta of 2.00. The company’s 50-day moving average price is $4.09 and its 200-day moving average price is $3.62. Clover Health Investments, Corp. has a 1-year low of $0.61 and a 1-year high of $4.87.

Institutional Investors Weigh In On Clover Health Investments

Several hedge funds and other institutional investors have recently modified their holdings of CLOV. Concurrent Investment Advisors LLC bought a new stake in Clover Health Investments in the 3rd quarter valued at $28,000. Sigma Planning Corp bought a new stake in shares of Clover Health Investments in the third quarter valued at about $29,000. Parallax Volatility Advisers L.P. acquired a new stake in Clover Health Investments during the third quarter worth about $38,000. Triumph Capital Management bought a new position in Clover Health Investments during the fourth quarter valued at about $45,000. Finally, KBC Group NV acquired a new position in Clover Health Investments in the 3rd quarter valued at approximately $53,000. Institutional investors and hedge funds own 19.77% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on CLOV shares. Canaccord Genuity Group boosted their price target on Clover Health Investments from $4.20 to $4.50 and gave the stock a “buy” rating in a research report on Monday, March 3rd. Craig Hallum started coverage on shares of Clover Health Investments in a research report on Tuesday, December 17th. They issued a “buy” rating and a $6.00 price target on the stock.

Clover Health Investments Company Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.